Meeting
2019 Genitourinary Cancers Symposium
Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.
Authors
Seanthel Delos Santos
Sunnybrook Research Institute, Toronto, ON, Canada
Seanthel Delos Santos , Cameron Phillips , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 270)
DOI
10.1200/JCO.2019.37.7_suppl.270
Abstract #
270
Poster Bd #
M5
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.
First Author: Robert H. Getzenberg
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
Management disparities in metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Nataliya Mar